	US 11,771,660 B2
	Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof
Yuling Liu, Beijing (CN); Hengfeng Liao, Beijing (CN); Yue Gao, Beijing (CN); Wujun Dong, Beijing (CN); Zhihua Liu, Beijing (CN); Bangyuan Wang, Beijing (CN); Yun Zhang, Beijing (CN); Yu Feng, Beijing (CN); Junzhuo Zhou, Beijing (CN); Lu Liu, Beijing (CN); Jun Ye, Beijing (CN); Yanfang Yang, Beijing (CN); and Xuejun Xia, Beijing (CN)
Assigned to BEIJING WEHAND-BIO PHARMACEUTICAL CO., LTD., Beijing (CN); and INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCE & PEKING UNION MEDICAL COLLEGE, Beijing (CN)
Appl. No. 17/602,423
Filed by BEIJING WEHAND-BIO PHARMACEUTICAL CO., LTD., Beijing (CN); and INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCE & PEKING UNION MEDICAL COLLEGE, Beijing (CN)
PCT Filed Apr. 8, 2020, PCT No. PCT/CN2020/083837 § 371(c)(1), (2) Date Oct. 8, 2021, PCT Pub. No. WO2020/207417, PCT Pub. Date Oct. 15, 2020.
Claims priority of application No. 201910278955.6 (CN), filed on Apr. 9, 2019.
Prior Publication US 2022/0168237 A1, Jun. 2, 2022
Int. Cl. A61K 31/05 (2006.01); A61P 39/06 (2006.01); A61P 9/10 (2006.01); A61P 31/00 (2006.01); A61P 1/16 (2006.01); A61P 3/06 (2006.01); A61P 9/12 (2006.01); A61P 35/00 (2006.01); A61K 9/107 (2006.01); A61K 31/12 (2006.01); A61K 31/352 (2006.01); A61K 45/00 (2006.01); A61K 47/22 (2006.01); A61K 36/539 (2006.01)

CPC A61K 31/05 (2013.01) [A61K 9/1075 (2013.01); A61K 31/12 (2013.01); A61K 31/352 (2013.01); A61K 45/00 (2013.01); A61K 47/22 (2013.01); A61P 1/16 (2018.01); A61P 3/06 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 39/06 (2018.01); A61K 36/539 (2013.01)]

16 Claims

1. A polyphenol drug self-emulsifying composition, comprising a polyphenol drug-phospholipid complex, an oil phase, an emulsifier and a co-emulsifier, wherein the polyphenol drug is baicalein;

wherein in the polyphenol drug-phospholipid complex, a mass ratio of the polyphenol drug to phospholipid is 1:1-1:8;

wherein the oil phase is one or more selected from the group consisting of ethyl oleate, isopropyl myristate and caprylic capric glyceride;

wherein the emulsifier is one or more selected from the group consisting of caprylic capric polyethylene glycol glyceride, Tween 80, and octyl phenyl polyoxyethylene ether;

wherein the co-emulsifier is selected from propylene glycol monocaprylate and/or diethylene glycol monoethyl ether; and

wherein the oil phase accounts for 10-30%, the emulsifier accounts for 40-60%, and the co-emulsifier accounts for 30-40%, provided that the total mass of the oil phase, the emulsifier and the co-emulsifier is 100%.